NCT00822614View on ClinicalTrials.gov

Safety of Fentanyl TAIFUN Treatment

PHASE3UnknownINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

December 31, 2009

Study Completion Date

January 31, 2010

Conditions
Breakthrough Cancer Pain
Interventions
DRUG

Fentanyl TAIFUN

Inhalation of Fentanyl via TAIFUN inhaler

DRUG

Opioid

Current optimized BTP treatment

Trial Locations (1)

4487-800

RECRUITING

NZOZ, Włocławek

Sponsors

Lead Sponsor

Akela Pharma, Inc.
All Listed Sponsors
lead

Akela Pharma, Inc.

INDUSTRY

NCT00822614 - Safety of Fentanyl TAIFUN Treatment | Biotech Hunter | Biotech Hunter